Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
In gastric cancer the Astra/Daiichi drug could tie a second string to its bow, but toxicities might put a dampener on forecasts.
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.
The Paola-1 study of Astrazeneca and Merck & Co’s Lynparza plus Avastin shows that more ovarian cancer patients can benefit from Parp inhibition, though the role of…